Intervention Protocol

Selective cyclooxygenase 2 inhibitors for the treatment of rheumatological manifestations of inflammatory bowel disease

  1. Xin-Pu Miao2,
  2. Jian-Sheng Li3,
  3. Qin Ouyang1,*,
  4. Ren-Wei Hu1,
  5. Yan Zhang4,
  6. Hui-Yan Li5

Editorial Group: Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group

Published Online: 15 APR 2009

DOI: 10.1002/14651858.CD007744


How to Cite

Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY. Selective cyclooxygenase 2 inhibitors for the treatment of rheumatological manifestations of inflammatory bowel disease (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007744. DOI: 10.1002/14651858.CD007744.

Author Information

  1. 1

    West China Hospital of Sichuan University, Gastroenterology, Chengdu, Sichuan, China

  2. 2

    the Affiliated Hospital of Hainan Medical College, Gastroenterology, Haikou, Hainan Province, China

  3. 3

    First Affiliated Hospital of Zhengzhou University, Department of Gastroenterology, Zhengzhou, Henan Province, China

  4. 4

    The Beijing Hospital of Traditional Chinese Medical, Department of Acupuncture and Moxibustion, Beijing, Beijing, China

  5. 5

    West China Hospital of Sichuan University, Departement of Chemotherapy, Chengdu, Sichuan, China

*Qin Ouyang, Gastroenterology, West China Hospital of Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China. ouyangqin1@sina.com.

Publication History

  1. Publication Status: New
  2. Published Online: 15 APR 2009

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this study is to evaluate the tolerability of COX-2 inhibitors (celecoxib, rofecoxib, valdecoxib, etoricoxib, and lumiracoxib) for the treatment the rheumatological manifestations of IBD and to identify gaps in knowledge that will suggest the most fruitful direction for future research.